Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Sareum Holdings plc
  6. News
  7. Summary
    SAR   GB00B02RFS12

SAREUM HOLDINGS PLC

(SAR)
  Report
Delayed Quote. Delayed London Stock Exchange - 10/21 10:02:59 am
6.69 GBX   -0.89%
04:44aSAREUM : Notice of Results
PU
10/07SAREUM : US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor
PU
09/29SAREUM : Reference to SRA737 Timeline at Cantor Conference
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Sareum : to Present at BioTrinity 2021 Conference

06/22/2021 | 05:17am EDT

Sareum Holdings plc

('Sareum' or the 'Company')

Sareum to Present at BioTrinity 2021 Conference

Cambridge, UK, 21 June 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company, announces that its CEO, Dr Tim Mitchell, will give a company presentation at 10:30am BST today at the BioTrinity 2021 conference.

In his presentation, Dr Mitchell will showcase Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes: SDC-1801 targeting autoimmune diseases and the severe inflammatory responses and respiratory symptoms arising from Covid-19 and other viral infections, and SDC-1802 targeting cancers.

The presentation is available to delegates of BioTrinity 2021, and a copy of the slides will be made publicly available on Sareum's website after the presentation - www.sareum.com.

About BioTrinity

BioTrinity is a highly regarded biopartnering & investment life sciences conference, that aims to shine a light on new innovation in the life sciences industry and inspire growth and create opportunities for all who attend.

The 2021 event will be delivered in a true hybrid format, and will provide seamless live interaction for delegates, who include early-stage and emerging biotech, medtech and digital health companies, big pharma executives, life sciences investors and service providers.

BioTrinity 2021 will be delivered live in a hybrid format at etc. venues Bishopsgate, London and via a dedicated virtual platform on Monday 21 & Tuesday 22 June in person, with the virtual platform available until Friday 25 June. For more information on the BioTrinity event, please visit www.biotrinity.com.

For further information, please contact:

Sareum Holdings plc

Tim Mitchell, CEO

01223 497 700

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

020 7409 3494

Hybridan LLP (Nominated Broker)

Claire Noyce

020 3764 2341

MEDiSTRAVA Consulting (Financial PR)

Mark Swallow/ David Dible

020 7638 9571

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

- Ends -

Disclaimer

Sareum Holdings plc published this content on 21 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 June 2021 09:16:04 UTC.


© Publicnow 2021
All news about SAREUM HOLDINGS PLC
04:44aSAREUM : Notice of Results
PU
10/07SAREUM : US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor
PU
09/29SAREUM : Reference to SRA737 Timeline at Cantor Conference
PU
07/30SAREUM : Shares Jump 8% on Incoming Cancer Treatment Patent
MT
07/30SAREUM : Patent Notice of Allowance for SDC-1802
PU
07/21Sareum Holdings plc Provides Financial Guidance for Fiscal 2021
CI
07/19FTSE 100 Closes Down as Covid Cases Rise
DJ
07/19ALAN JOPE : FTSE 100 Slides as Virus Jitters Weigh
DJ
07/19SAREUM : Subscription to raise £1,000,000
PU
07/01SAREUM : Completed Covid-19 Research Project Delivers Encouraging Results
PU
More news
Financials
Sales 2021 0,17 M 0,23 M 0,23 M
Net income 2021 -1,63 M -2,25 M -2,25 M
Net Debt 2021 - - -
P/E ratio 2021 -135x
Yield 2021 -
Capitalization 227 M 314 M 314 M
Capi. / Sales 2021 1 336x
Capi. / Sales 2022 -
Nbr of Employees 6
Free-Float 95,6%
Chart SAREUM HOLDINGS PLC
Duration : Period :
Sareum Holdings plc Technical Analysis Chart | SAR | GB00B02RFS12 | MarketScreener
Technical analysis trends SAREUM HOLDINGS PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,07 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Timothy John Mitchell Chief Executive Officer & Executive Director
Stephen B. Parker Non-Executive Chairman
John Charles Reader Executive Director & Chief Scientific Officer
Clive Birch Independent Non-Executive Director
Michael John Owen Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SAREUM HOLDINGS PLC178.35%314
GILEAD SCIENCES, INC.14.76%83 830
BIONTECH SE230.50%65 071
WUXI APPTEC CO., LTD.25.14%64 894
REGENERON PHARMACEUTICALS16.48%58 504
VERTEX PHARMACEUTICALS-21.52%48 121